These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17346111)

  • 1. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Urata Y; Tanaka N
    Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
    Fujiwara T; Urata Y; Tanaka N
    Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
    Fujiwara T; Kagawa S; Tazawa H
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Tanaka N
    Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase-specific replication-selective virotherapy for human cancer.
    Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oncolytic virotherapy for human solid tumors].
    Fujiwara T
    Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
    Fujiwara T; Tanaka N
    Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.
    Fujiwara T; Shirakawa Y; Kagawa S
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):525-32. PubMed ID: 21504319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer.
    Fujiwara T
    Acta Med Okayama; 2011 Jun; 65(3):151-62. PubMed ID: 21709712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary oncolytic virotherapy for gastrointestinal cancer.
    Fujiwara T
    Ann Gastroenterol Surg; 2019 Jul; 3(4):396-404. PubMed ID: 31346579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
    Doloff JC; Jounaidi Y; Waxman DJ
    Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase-specific virotherapy for human squamous cell carcinoma.
    Fujiwara T
    Expert Opin Biol Ther; 2009 Mar; 9(3):321-9. PubMed ID: 19216621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
    Bilsland AE; Merron A; Vassaux G; Keith WN
    Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
    Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.
    Doloff JC; Waxman DJ; Jounaidi Y
    Hum Gene Ther; 2008 Dec; 19(12):1383-400. PubMed ID: 18771358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
    Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
    Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.
    Wirth T; Zender L; Schulte B; Mundt B; Plentz R; Rudolph KL; Manns M; Kubicka S; Kühnel F
    Cancer Res; 2003 Jun; 63(12):3181-8. PubMed ID: 12810646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.